PHATHOM PHARMACEUTICALS, INC. (PHAT): Price and Financial Metrics
PHAT Price/Volume Stats
| Current price | $9.17 | 52-week high | $17.02 |
| Prev. close | $9.48 | 52-week low | $6.07 |
| Day low | $8.94 | Volume | 271,823 |
| Day high | $9.88 | Avg. volume | 844,472 |
| 50-day MA | $9.53 | Dividend yield | N/A |
| 200-day MA | $10.27 | Market Cap | 536.67M |
PHAT Stock Price Chart Interactive Chart >
PHATHOM PHARMACEUTICALS, INC. (PHAT) Company Bio
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
Latest PHAT News From Around the Web
Below are the latest news stories about PHATHOM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PHAT as an investment opportunity.
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules CapitalAmendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027Up to an additional $100 million in non-dilutive capital available subject to the achievement of certain revenue milestonesCash runway now expected through the end of 2026 FLORHAM PARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for g |
Several Insiders Invested In Phathom Pharmaceuticals Flagging Positive NewsGenerally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying... |
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERDNew drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERDJuly 19, 2024 PDUFA target action date assigned by the FDA FLORHAM PARK, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the FDA has |
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated HeartburnVOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channelVOQUEZNA tablets in 30-count bottles are now commercially available for the healing and maintenance of healing of all severities of Erosive GERD, and relief of heartburn associated with Erosive GERD1 FLORHAM PARK, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmac |
Phathom Pharmaceuticals Inc (PHAT) Reports Q3 2023 Financial ResultsKey Takeaways from the Third Quarter Earnings Report |
PHAT Price Returns
| 1-mo | 0.55% |
| 3-mo | 22.43% |
| 6-mo | -0.97% |
| 1-year | -11.32% |
| 3-year | -74.10% |
| 5-year | N/A |
| YTD | 0.44% |
| 2023 | -18.63% |
| 2022 | -42.96% |
| 2021 | -40.79% |
| 2020 | 6.68% |
| 2019 | N/A |
Loading social stream, please wait...